β-Secretase Inhibitor IV is a cellular permeability inhibitor that binds to the active site of BACE-1 and blocks its proteolytic activity (IC₅₀= 15 nM in human BACE-1).
GP130 receptor agonist-1 is a potent, brain-penetrant and orally active GP130 receptor agonist. GP130 receptor agonist-1 has a neuroprotective effect on NMDA-induced neurotoxicity.
GP130 receptor agonist-1 is a potent, brain-penetrant and orally active GP130 receptor agonist. GP130 receptor agonist-1 has a neuroprotective effect on NMDA-induced neurotoxicity.
Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM.
VU661013 is a novel, potent, selective MCL1 inhibitor with Ki of 97 ± 30 pM to human MCL-1 in a TR-FRET assay. VU661013 destabilizes BIM/MCL1 association, leads to apoptosis in AML, and is active in venetoclax-resistant cells and xenografts.
Bimagrumab (BYM338) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
Bimagrumab (BYM338) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
Mazdutide (IBI362, LY3305677) is a novel glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. It can be used in studies of obesity and type 2 diabetes (T2D).
Mazdutide (IBI362, LY3305677) is a novel glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. It can be used in studies of obesity and type 2 diabetes (T2D).
IPI-9119 is an orally active, selective and irreversible Fatty Acid Synthase (FASN) inhibitor, with an IC50 of 0.3 nM.